Pharmacy Regulatory Affairs MCQs

Below is an advanced, conceptual MCQ set covering the regulatory topics you specified. The questions are designed to test application, distinctions between laws/rules, regulatory authorities, definitions, exemptions, approval pathways, and numerical/legal provisions: questions in GPAT, NIPER, AIIMS Pharmacist, SSC, ESIC, Railway Pharmacist, and State Pharmacist examinations.

Section A: Medical Termination of Pregnancy Act

1. The principal objective of the Medical Termination of Pregnancy (MTP) law is to:

A. Legalize abortion without any conditions
B. Regulate termination of certain pregnancies by qualified medical practitioners under specified conditions
C. Permit termination only when pregnancy results from marriage
D. Replace contraception with medical termination

Answer: B

Explanation: The MTP framework permits termination of pregnancy under specified circumstances and conditions, by appropriately qualified medical practitioners. It is therefore a regulated medical procedure rather than an unrestricted right.

2. Under the amended MTP framework, termination of pregnancy up to 20 weeks may generally be performed by:

A. Any registered pharmacist
B. One registered medical practitioner, subject to the statutory conditions
C. Only a two-member Medical Board
D. Only a gynecologist appointed by the Central Government

Answer: B

Explanation: For pregnancies up to 20 weeks, the amended law permits termination by one Registered Medical Practitioner (RMP) when the statutory conditions are fulfilled.

3. For pregnancies exceeding 20 weeks but not exceeding 24 weeks, termination is permitted for specified categories of women when:

A. Approved by any pharmacist
B. Approved by one RMP without further conditions
C. The prescribed statutory requirements, including the opinion of the required medical practitioners, are satisfied
D. Requested by the husband

Answer: C

Explanation: The 2021 amendment expanded access in the 20–24-week period for specified categories of women, subject to prescribed conditions and medical opinion.

4. Which of the following is an important conceptual change introduced by the MTP Amendment Act, 2021?

A. Removal of all gestational limits
B. Expansion of the permissible gestational limit in specified circumstances and recognition of confidentiality requirements
C. Abolition of medical practitioner requirements
D. Transfer of abortion regulation entirely to pharmacists

Answer: B

Explanation: The 2021 amendment expanded access in specified circumstances and strengthened the confidentiality of the woman's identity and particulars.

5. A woman seeks termination of pregnancy within the legally permitted period. Her identity is disclosed publicly by a person who obtained the information through the termination procedure. Which principle is most directly implicated?

A. Patent protection
B. Confidentiality under the MTP framework
C. Drug-price control
D. Clinical-trial compensation

Answer: B

Explanation: The MTP framework contains provisions protecting the privacy and confidentiality of the woman undergoing termination.

6. A Medical Board becomes particularly relevant under the amended MTP framework when:

A. Every pregnancy is below 12 weeks
B. Pregnancy exceeds 24 weeks and falls within specified statutory circumstances involving substantial fetal abnormalities
C. A woman requests contraception
D. A pharmacist dispenses an OTC medicine

Answer: B

Explanation: The amended framework provides for medical boards in specified cases, particularly involving substantial fetal abnormalities where termination is sought beyond the ordinary gestational limits.

Section B: Right to Information Act, 2005

7. The fundamental objective of the Right to Information Act, 2005 is to:

A. Protect government information from citizens
B. Promote transparency and accountability in public authorities
C. Regulate pharmaceutical advertisements
D. Control drug prices

Answer: B

Explanation: The RTI Act promotes transparency and accountability by providing citizens access to information held by public authorities, subject to statutory exemptions.

8. Which of the following is NOT ordinarily the objective of the RTI Act?

A. Increasing transparency
B. Promoting accountability
C. Containing corruption
D. Granting unrestricted access to every confidential government document

Answer: D

Explanation: RTI provides a statutory right of access but contains exemptions and limitations designed to protect specified interests such as national security, privacy and certain confidential information.

9. A pharmaceutical college is a public authority under the applicable RTI framework. A citizen requests information held by the institution. Which mechanism is primarily responsible for processing such an RTI request?

A. Drug Inspector
B. Public Information Officer
C. Pharmacy Council
D. Medical Board

Answer: B

Explanation: A Public Information Officer (PIO) is designated to receive and process requests for information under the RTI framework.

10. Which statement best describes the relationship between RTI and confidentiality?

A. RTI completely overrides confidentiality
B. Confidentiality always overrides RTI
C. RTI provides access subject to specified statutory exemptions
D. RTI applies only to pharmaceutical information

Answer: C

Explanation: RTI is based on transparency, but the Act contains specific exemptions. The correct approach is therefore to balance disclosure against legally protected interests.

Section C: New Drugs and Clinical Trials Rules, 2019

11. The New Drugs and Clinical Trials Rules (NDCTR), 2019 were framed primarily under which legislation?

A. Pharmacy Act, 1948
B. Drugs and Cosmetics Act, 1940
C. Medical Termination of Pregnancy Act
D. Food Safety and Standards Act, 2006

Answer: B

Explanation: NDCTR 2019 were framed under the Drugs and Cosmetics Act, 1940 and provide a modern regulatory framework for new drugs, clinical trials and related matters.

12. Which authority is primarily responsible for regulation of new drugs and clinical trials at the central level?

A. FSSAI
B. CDSCO/DCGI
C. PCI
D. NPPA

Answer: B

Explanation: The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), plays the central regulatory role in new-drug and clinical-trial approvals.

13. Under NDCTR 2019, which body has a critical role in protecting the rights, safety and well-being of clinical-trial participants at the institutional level?

A. NPPA
B. Institutional Ethics Committee
C. Pharmacy Council
D. State Pharmacy Council

Answer: B

Explanation: The Ethics Committee/Institutional Ethics Committee (IEC) reviews clinical research from an ethical and participant-safety perspective.

14. Which of the following best differentiates a clinical trial from a bioavailability study?

A. Clinical trials never involve human participants
B. Bioavailability studies may assess the rate and extent of absorption, whereas clinical trials primarily investigate clinical effects and safety/efficacy
C. Clinical trials are conducted only in animals
D. Bioavailability has no regulatory relevance

Answer: B

Explanation: Bioavailability concerns the rate and extent to which the active ingredient becomes available at the site of action/systemic circulation, whereas clinical trials evaluate therapeutic effects and safety.

15. A sponsor conducts a clinical trial without obtaining the required regulatory and ethics approvals. Which principle has been violated?

A. Market-based pricing
B. Prior regulatory and ethical oversight of clinical research
C. Cosmetic labeling
D. Food fortification

Answer: B

Explanation: Clinical trials require appropriate regulatory permission and ethics oversight before initiation, subject to the applicable provisions.

16. Under NDCTR 2019, which of the following is most closely associated with compensation provisions?

A. Compensation for specified trial-related injury or death
B. Compensation for every adverse event regardless of causality
C. Compensation exclusively to pharmaceutical companies
D. Compensation for loss of market share

Answer: A

Explanation: The clinical-trial framework contains provisions concerning medical management and compensation for clinical-trial-related injury or death, subject to applicable rules.

17. Which concept is most important when determining whether an adverse event is a serious adverse event (SAE)?

A. The colour of the dosage form
B. The seriousness criteria such as death, life-threatening condition, hospitalization or significant disability
C. The brand name
D. The MRP

Answer: B

Explanation: SAE classification is based on clinical seriousness, including outcomes such as death, life-threatening events, hospitalization, disability and other medically important events.

18. A new drug is proposed for a condition for which adequate approved therapies already exist. Which factor becomes particularly important to the regulator?

A. Whether the proposed drug offers an acceptable benefit-risk profile and appropriate evidence
B. Whether the packaging is attractive
C. Whether its MRP is higher
D. Whether the manufacturer has a large advertising budget

Answer: A

Explanation: Regulatory evaluation focuses on quality, safety and efficacy, including the benefit-risk profile and adequacy of evidence.

Section D: Cosmetics Rules, 2020

19. The Cosmetics Rules, 2020 primarily regulate:

A. Manufacture, import, labelling and sale of cosmetics under the applicable legal framework
B. Clinical trials of vaccines
C. Drug price fixation
D. Food fortification

Answer: A

Explanation: The Cosmetics Rules, 2020 provide a comprehensive framework concerning cosmetics, including manufacture, import, standards, labelling and related regulatory requirements.

20. Which legislation provides the principal statutory foundation for the Cosmetics Rules, 2020?

A. Drugs and Cosmetics Act, 1940
B. Food Safety and Standards Act, 2006
C. Pharmacy Act, 1948
D. NDPS Act, 1985

Answer: A

Explanation: The Cosmetics Rules, 2020 were framed under the Drugs and Cosmetics Act, 1940.

21. Which of the following is a major regulatory concern in cosmetic regulation?

A. Product safety and compliance with prescribed standards
B. Only therapeutic efficacy
C. Only retail price
D. Only patent status

Answer: A

Explanation: Cosmetics are regulated primarily with emphasis on quality, safety, standards, manufacturing and labeling requirements.

22. A product is marketed with claims that it treats or cures a disease. Why could this create a regulatory issue?

A. Because the claim may cause the product to be considered as having a therapeutic/drug-related claim rather than merely a cosmetic function
B. Because all cosmetics are automatically banned
C. Because cosmetics cannot have labels
D. Because every cosmetic becomes an antibiotic

Answer: A

Explanation: The intended use and claims of a product are important in determining its regulatory classification. Therapeutic claims can move a product beyond the ordinary cosmetic category.

Section E: Similar Biologics

23. The principal objective of guidelines on similar biologics is to establish:

A. A pathway for development and regulatory evaluation of biologic products similar to an already approved reference biologic
B. A pathway for generic tablets only
C. Rules for cosmetic advertisements
D. Rules for food additives

Answer: A

Explanation: Similar-biologic regulation provides a framework for demonstrating comparability with a reference biologic, considering quality, safety and efficacy.

24. Which analytical approach is particularly important during development of a similar biologic?

A. Comparative characterization of physicochemical and biological attributes
B. Only comparison of package colour
C. Only comparison of MRP
D. Only comparison of tablet hardness

Answer: A

Explanation: Biologics are structurally complex. Therefore, extensive analytical and functional characterization is essential for demonstrating similarity.

25. Why is a conventional generic-drug approach insufficient for many biologics?

A. Biologics are generally structurally more complex and may exhibit manufacturing-process-dependent characteristics
B. Biologics contain no active ingredients
C. Biologics cannot be tested
D. Generic drugs are always more expensive

Answer: A

Explanation: Unlike many small-molecule drugs, biologics are highly complex and their characteristics can depend significantly on the manufacturing process. Hence, a biosimilar/similar-biologic approach relies heavily on comparability.

26. Which principle is central to similar-biologic development?

A. Demonstration of similarity rather than complete duplication of the reference product
B. Identical manufacturing process in every detail
C. Identical brand name
D. Absence of analytical testing

Answer: A

Explanation: The objective is to demonstrate that the proposed product is highly similar to the reference biologic, with no clinically meaningful differences in relevant attributes, subject to the applicable regulatory framework.

Section F: Medical Device Regulations

27. India's Medical Device Rules, 2017 were primarily framed under:

A. Drugs and Cosmetics Act, 1940
B. Pharmacy Act, 1948
C. Food Safety and Standards Act, 2006
D. RTI Act, 2005

Answer: A

Explanation: Medical Device Rules, 2017 were framed under the Drugs and Cosmetics Act, 1940 and established a dedicated framework for medical-device regulation.

28. Risk-based classification of medical devices is important because:

A. Higher-risk devices generally require greater regulatory scrutiny
B. All devices have identical regulatory requirements
C. Risk classification determines only the colour of packaging
D. Risk classification is relevant only to cosmetics

Answer: A

Explanation: A risk-based approach allows regulatory controls to be proportionate to the potential harm associated with the device.

29. A medical device that presents greater potential risk to patients would generally be expected to undergo:

A. Less regulatory scrutiny
B. Greater regulatory scrutiny and evidence requirements
C. No quality assessment
D. Only advertising approval

Answer: B

Explanation: The fundamental logic of risk-based regulation is greater oversight for higher-risk products.

30. Which organization is central to India's regulation of medical devices at the central level?

A. CDSCO
B. NPPA alone
C. PCI
D. FSSAI

Answer: A

Explanation: CDSCO is the principal central regulatory authority for medical devices, while State Licensing Authorities also have roles under the applicable regulatory framework.

Section G: Probiotics

31. Which characteristic is most important when considering a microorganism as a probiotic?

A. It must be beneficial to health when administered in adequate amounts
B. It must always cause infection
C. It must be genetically identical to a pathogen
D. It must contain antibiotics

Answer: A

Explanation: Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.

32. Which statement best differentiates probiotics from prebiotics?

A. Probiotics are live microorganisms; prebiotics are substrates selectively utilized by beneficial microorganisms
B. Both are identical
C. Probiotics are enzymes and prebiotics are antibiotics
D. Probiotics are minerals and prebiotics are vitamins

Answer: A

Explanation: Probiotics = beneficial live microorganisms.
Prebiotics = substrates selectively utilized by beneficial microorganisms.

33. A probiotic product claims that its microorganism improves a particular health outcome. Which evidence is most valuable for substantiating such a specific health claim?

A. Appropriate scientific evidence supporting the claimed effect
B. Attractive packaging
C. Low MRP
D. High advertising expenditure

Answer: A

Explanation: Health-related claims require scientific substantiation appropriate to the claim and applicable regulatory requirements.

Section H: FSSAI Regulations: Health Supplements & Nutraceuticals

34. The Food Safety and Standards Act, 2006 primarily deals with:

A. Regulation of food safety and standards
B. Clinical trials of new drugs
C. Medical termination of pregnancy
D. Pharmaceutical price fixation

Answer: A

Explanation: FSSAI operates under the Food Safety and Standards Act, 2006, which establishes the framework for food safety and standards in India.

35. Which authority is responsible for regulating foods, including health supplements and nutraceuticals, under the relevant food-safety framework?

A. FSSAI
B. NPPA
C. CDSCO exclusively
D. PCI

Answer: A

Explanation: The Food Safety and Standards Authority of India (FSSAI) regulates food products under the FSS Act and associated regulations.

36. Which statement best distinguishes a nutraceutical from a conventional pharmaceutical drug?

A. A nutraceutical is regulated within the food regulatory framework, whereas pharmaceutical drugs fall primarily under drug regulation
B. Nutraceuticals are always prescription medicines
C. Drugs are regulated by FSSAI exclusively
D. Nutraceuticals cannot contain biologically active substances

Answer: A

Explanation: Nutraceuticals and related products covered under FSSAI regulations are regulated as food products, while pharmaceutical drugs are primarily regulated under the drugs-and-cosmetics framework.

37. Which of the following is most likely to raise a regulatory concern for a health supplement?

A. A claim that it diagnoses and cures a serious disease
B. Declaration of ingredients
C. Appropriate labeling
D. Stating nutritional information

Answer: A

Explanation: Health supplements and nutraceuticals are subject to restrictions on disease-treatment/cure claims. Such claims can create a regulatory classification problem.

38. Food for Special Medical Purpose (FSMP) is conceptually intended for:

A. Individuals with specific medical conditions whose dietary management requires specially formulated food
B. Healthy individuals seeking recreational drugs
C. Cosmetic treatment
D. Veterinary surgical procedures

Answer: A

Explanation: FSMP is intended for the dietary management of individuals with specific medical conditions, generally under medical supervision as appropriate.

39. Food for Special Dietary Use (FSDU) is primarily associated with:

A. Foods formulated to meet particular dietary requirements resulting from a specific physiological or health condition
B. Injectable antibiotics
C. Surgical implants
D. Prescription-only medicines

Answer: A

Explanation: FSDU products are specially formulated to address specific dietary requirements, distinguishing them from ordinary foods.

40. Which of the following best describes “novel food”?

A. A food or ingredient with characteristics falling within the regulatory concept of a food not traditionally consumed or otherwise meeting specified novelty criteria
B. Any newly packaged conventional food
C. Any imported medicine
D. Any cosmetic introduced after 2020

Answer: A

Explanation: Novel foods are subject to specific regulatory provisions because of their novelty and/or history of use, requiring compliance with applicable safety and approval requirements.

Section I: Integrated Conceptual Questions

41. A company develops a live microbial product and markets it as a product that “cures irritable bowel syndrome.” Which regulatory issue should be considered first?

A. Whether the product is being presented merely as a food/probiotic or with a therapeutic disease claim
B. Whether the package contains enough colours
C. Whether the product has a patent
D. Whether the retailer margin is 16%

Answer: A

Explanation: The nature of the claims is critical. A disease-treatment claim may create regulatory consequences beyond ordinary food/probiotic positioning.

42. A monoclonal antibody is developed to be highly similar to an already approved reference biologic. Which regulatory pathway is most conceptually appropriate?

A. Similar-biologic/biosimilar pathway
B. Cosmetic registration pathway
C. FSSAI nutraceutical pathway
D. RTI pathway

Answer: A

Explanation: A biologic intended to demonstrate similarity to an approved reference biologic is evaluated under the similar-biologic/biosimilar regulatory framework.

43. A company wants to introduce an implantable high-risk medical device. Which regulatory philosophy would be most appropriate?

A. Risk-based assessment with greater scrutiny for higher-risk devices
B. Same requirements as a low-risk cosmetic
C. No clinical or technical evaluation
D. Only FSSAI approval

Answer: A

Explanation: High-risk medical devices require more stringent evaluation because the consequences of device failure may be substantial.

44. Which pairing is INCORRECT?

A. NPPA — Drug price regulation
B. CDSCO — New drugs and medical devices
C. FSSAI — Food and nutraceutical regulation
D. PCI — Clinical trial authorization

Answer: D

Explanation: PCI regulates pharmacy education and professional matters. Clinical-trial and new-drug regulatory functions fall primarily under the CDSCO/DCGI framework.

45. Which pair correctly matches the regulatory framework with its principal subject?

A. NDCTR 2019 — New drugs and clinical trials
B. Cosmetics Rules 2020 — Drug price fixation
C. RTI Act — Nutraceutical approval
D. FSSAI regulations — Clinical trial compensation

Answer: A

Explanation: NDCTR 2019 specifically governs regulatory matters concerning new drugs and clinical trials. The other pairings incorrectly assign regulatory functions.

46. Assertion–Reason

Assertion (A): Similar biologics cannot be regulated using exactly the same conceptual approach as conventional small-molecule generic drugs.

Reason (R): Biologics are complex molecules whose characteristics can be influenced by the manufacturing process.

A. Both A and R are true, and R correctly explains A
B. Both A and R are true, but R does not explain A
C. A is true, R is false
D. A is false, R is true

Answer: A

Explanation: Biologics have complex structures and manufacturing-dependent characteristics. Therefore, comparability and extensive characterization are central to their regulatory pathway.

47. Assertion–Reason

Assertion (A): The RTI Act provides an absolute right to obtain every document held by a public authority.

Reason (R): The RTI Act contains statutory exemptions from disclosure.

A. Both A and R are true, and R correctly explains A
B. Both A and R are true, but R does not explain A
C. A is false, R is true
D. A is true, R is false

Answer: C

Explanation: The RTI Act establishes a strong right of access but not an absolute right. Statutory exemptions restrict disclosure in specified circumstances.

48. A company sells a product as a “nutraceutical” but labels it as a medicine capable of curing diabetes. Which is the strongest regulatory concern?

A. The claim may be inconsistent with the permissible positioning of a food/nutraceutical product
B. Nutraceuticals must always be prescription-only
C. All nutraceuticals are prohibited
D. The product automatically becomes a medical device

Answer: A

Explanation: Disease cure/treatment claims are a major regulatory boundary between food/nutraceutical products and medicines.

49. Which of the following represents the correct regulatory chain?

A. Clinical trial → Ethics Committee review → Regulatory oversight → Participant protection
B. Clinical trial → Advertisement → Pharmacy Council → FSSAI
C. Medical device → NPPA → MTP Board → RTI
D. Nutraceutical → DCGI → Pharmacy Council → MTP Board

Answer: A

Explanation: Ethical review and regulatory oversight are essential components of responsible clinical research, with participant safety and rights being central considerations.

50. A pharmaceutical professional must determine whether a new product should be regulated primarily as a drug, cosmetic, medical device or food. Which factor is most important?

A. Product's intended use, composition, claims, and applicable statutory definitions
B. Manufacturer's preferred regulatory category
C. Colour of the package
D. Retail price alone

Answer: A

Explanation: Regulatory classification depends on the product's intended use, composition, claims, mode of action and statutory definitions, rather than the manufacturer's preferred label.

Ultra-High-Yield Revision Points

• Topic Exam-focused point

• MTP Act Regulates termination under specified circumstances

• MTP Amendment 2021 Expanded access in specified categories and strengthened confidentiality

• Up to 20 weeks One RMP, subject to statutory conditions

• 20–24 weeks Specified categories + prescribed medical opinion

• Beyond 24 weeks Special provisions, particularly specified substantial fetal abnormalities

• Medical Board Important in specified cases involving substantial fetal abnormalities

• RTI Act 2005 Transparency + accountability

• RTI Right is subject to statutory exemptions

• NDCTR 2019 New drugs + clinical trials

• Central regulator CDSCO/DCGI

• Ethics Committee Participant rights, safety and well-being

• Clinical trial Regulatory + ethical approval required

• Cosmetics Rules 2020 Cosmetics manufacture/import/standards/labelling etc.

• Similar biologics Demonstrate similarity/comparability with reference biologic

• Biologics Complex, manufacturing-process-dependent

• Medical Devices Risk-based regulation

• Central device regulator CDSCO

• Probiotics Live microorganisms conferring health benefit when administered adequately

• FSSAI Food safety and standards

• Health supplements/nutraceuticals Food regulatory framework

• FSDU Special dietary requirements

• FSMP Dietary management of specific medical conditions

• Novel food Food/ingredient meeting specified novelty criteria

• Disease claims Major regulatory red flag for food/nutraceutical products

Most likely conceptual traps

1. MTP ≠ unrestricted abortion law: termination is permitted subject to statutory conditions.

2. The 20-week vs 24-week distinction is frequently tested.

3. RTI ≠ absolute disclosure: exemptions are important.

4. NDCTR 2019 ≠ FSSAI regulation: it operates under the drugs regulatory framework.

5. IEC ≠ CDSCO: ethics review and regulatory authorization are different functions.

6. Similar biologic ≠ ordinary generic: biological complexity makes comparability central.

7. Medical device regulation is risk-based.

8. Probiotic ≠ prebiotic.

9. Nutraceutical ≠ pharmaceutical drug.

10. FSDU ≠ FSMP: their regulatory definitions and intended dietary uses differ.

11. Disease-treatment/cure claims can create a major regulatory classification issue for food products.

12. FSSAI regulates foods; CDSCO regulates drugs and medical devices within its statutory framework.

Exam strategy: For these topics, focus especially on definitions + competent authority + approval pathway + statutory limits + exemptions + classification + distinctions between closely related terms. These are more likely to differentiate an advanced candidate from one relying only on factual memorization.

MCQs: Pharmaceutical Legislations: Committees and Development of Pharmaceutical Regulation

Below is a challenging, concept-oriented set of 25 MCQs designed in the style of questions commonly encountered in GPAT, NIPER, AIIMS Pharmacist, Railway Pharmacist, SSC, ESIC, and State Pharmacist examinations. The questions emphasize committee–year–chairman–recommendation associations, chronology, conceptual distinctions, and application-based reasoning.

A. Drugs Enquiry Committee (Chopra Committee)

1. The Drugs Enquiry Committee, popularly known as the Chopra Committee, was primarily constituted to investigate:

A. Pharmaceutical education and registration of pharmacists
B. The quality, manufacture, import and distribution of drugs in India
C. National family planning programmes
D. Reorganization of state health services

Answer: B

Explanation: The Drugs Enquiry Committee (1930–31), headed by Lt. Col. R. N. Chopra, examined the problems associated with drugs in India, including their import, manufacture, distribution and quality, and highlighted the need for comprehensive drug legislation.

2. Which committee is correctly matched with its principal significance in Indian pharmaceutical history?

A. Chopra Committee — First comprehensive review of drug control problems
B. Mudaliar Committee — Establishment of Central Drugs Standard Control Organisation
C. Hathi Committee — First investigation into indigenous drug quality
D. Bhore Committee — Introduction of Pharmacy Act, 1948

Answer: A

Explanation: The Chopra Committee was an important early milestone in identifying deficiencies in drug control and recommending regulatory measures. Its work helped create the foundation for subsequent pharmaceutical legislation.

3. A major consequence of the recommendations of the Drugs Enquiry Committee was the recognition that India needed:

A. Complete abolition of indigenous systems of medicine
B. A systematic framework for controlling drugs
C. Privatization of pharmaceutical manufacturing
D. Compulsory hospitalization of patients receiving medicines

Answer: B

Explanation: The committee emphasized the need for proper regulation of drugs, including control over manufacture, import and distribution, eventually contributing to the development of modern drug legislation.

B. Health Survey and Development Committee — Bhore Committee

4. The Health Survey and Development Committee is more commonly known as the:

A. Hathi Committee
B. Bhore Committee
C. Mudaliar Committee
D. Chopra Committee

Answer: B

Explanation: The Health Survey and Development Committee, chaired by Sir Joseph Bhore, is popularly known as the Bhore Committee. Its report was published in 1946.

5. Which of the following was a major philosophy of the Bhore Committee's recommendations?

A. Health services should focus predominantly on urban tertiary hospitals
B. Preventive and curative services should be integrated
C. Pharmaceutical manufacturing should be completely privatized
D. Medical education should be separated from health services

Answer: B

Explanation: The Bhore Committee strongly emphasized integration of preventive and curative health services, with health care being made accessible to the population.

6. Which committee is most closely associated with the concept of a comprehensive and integrated health service in India?

A. Chopra Committee
B. Bhore Committee
C. Hathi Committee
D. Mudaliar Committee

Answer: B

Explanation: The Bhore Committee (1946) advocated an integrated health system and emphasized preventive, promotive and curative aspects of health care.

7. The Bhore Committee's recommendations were particularly important because they viewed health as:

A. Primarily a hospital-based service
B. A comprehensive public-health responsibility
C. A commercial pharmaceutical activity
D. A function restricted to medical practitioners

Answer: B

Explanation: The committee adopted a broad public-health perspective and recommended an organized health service accessible to the population rather than a system centered only on hospitals.

C. Mudaliar Committee

8. The Health Survey and Planning Committee is popularly associated with:

A. R. N. Chopra
B. Sir Joseph Bhore
C. A. Lakshmanaswami Mudaliar
D. Jaisukhlal Hathi

Answer: C

Explanation: The Health Survey and Planning Committee, chaired by Dr. A. Lakshmanaswami Mudaliar, is known as the Mudaliar Committee. Its report was submitted in 1962.

9. Which committee primarily reviewed the progress made after the recommendations of the Bhore Committee?

A. Chopra Committee
B. Hathi Committee
C. Mudaliar Committee
D. Drugs Technical Advisory Board

Answer: C

Explanation: The Mudaliar Committee assessed the development of health services after the Bhore Committee and examined the adequacy and functioning of existing health infrastructure.

10. A key concern of the Mudaliar Committee was:

A. Expansion of pharmaceutical exports only
B. Strengthening existing health services before indiscriminate expansion
C. Abolition of primary health centres
D. Replacement of preventive medicine by curative medicine

Answer: B

Explanation: The Mudaliar Committee emphasized strengthening and improving existing health services, particularly the quality and functioning of health institutions, rather than merely expanding them numerically.

11. Which of the following pairs is INCORRECT?

A. Bhore Committee: 1946
B. Mudaliar Committee: 1962
C. Chopra Committee: 1930–31
D. Hathi Committee: 1946

Answer: D

Explanation: The Hathi Committee was constituted much later, in 1974, under Jaisukhlal Hathi. The year 1946 is associated with the Bhore Committee report.

D. Hathi Committee

12. The Hathi Committee was primarily concerned with:

A. Health insurance
B. Drug and pharmaceutical industry
C. Medical education
D. Hospital architecture

Answer: B

Explanation: The Hathi Committee, constituted in 1974 under Jaisukhlal Hathi, reviewed the drug and pharmaceutical industry in India and made recommendations concerning drug production, availability, pricing and the pharmaceutical sector.

13. Which committee is associated with the famous review of the drug and pharmaceutical industry in India during the 1970s?

A. Bhore Committee
B. Mudaliar Committee
C. Hathi Committee
D. Chopra Committee

Answer: C

Explanation: The Hathi Committee (1974) examined the Indian drug and pharmaceutical industry and its report became an important reference point in subsequent pharmaceutical policy development.

14. Consider the following statements regarding the Hathi Committee:

1. It examined the Indian pharmaceutical industry.

2. It considered issues related to drug availability and pricing.

3. It was constituted before the Chopra Committee.

Which statement(s) is/are correct?

A. 1 only
B. 1 and 2 only
C. 2 and 3 only
D. 1, 2 and 3

Answer: B

Explanation: Statements 1 and 2 are correct. The Hathi Committee was constituted in 1974, whereas the Chopra Committee was established in 1930–31.

15. Which committee's recommendations are most directly relevant when studying the historical development of policies aimed at making essential medicines available at reasonable prices?

A. Hathi Committee
B. Bhore Committee
C. Mudaliar Committee
D. Chopra Committee

Answer: A

Explanation: The Hathi Committee examined important issues concerning the pharmaceutical industry, including availability and pricing of medicines, making it particularly relevant to the evolution of pharmaceutical policy.

E. Chronology-Based Questions

16. Arrange the following committees in chronological order:

1. Hathi Committee

2. Chopra Committee

3. Mudaliar Committee

4. Bhore Committee

A. 2 → 4 → 3 → 1
B. 4 → 2 → 3 → 1
C. 2 → 3 → 4 → 1
D. 4 → 3 → 2 → 1

Answer: A

Explanation: The sequence is:

Chopra (1930–31) → Bhore (1946) → Mudaliar (1962) → Hathi (1974).

This chronology is a high-yield area for competitive examinations.

17. Which sequence correctly represents the progression from drug regulation → comprehensive health planning → health-service review → pharmaceutical-industry review?

A. Chopra → Bhore → Mudaliar → Hathi
B. Bhore → Chopra → Hathi → Mudaliar
C. Mudaliar → Bhore → Chopra → Hathi
D. Hathi → Mudaliar → Bhore → Chopra

Answer: A

Explanation: The committees represent progressively different stages of India's regulatory and health-policy development: Chopra focused on drugs; Bhore on comprehensive health planning; Mudaliar reviewed health services; and Hathi examined the pharmaceutical industry.

F. Matching-Type Conceptual MCQs

18. Match Column I with Column II:

• Column I Column II

• 1. Chopra Committeea. Pharmaceutical industry

• 2. Bhore Committeeb. Drug enquiry

• 3. Mudaliar Committeec. Health Survey and Development

• 4. Hathi Committeed. Health Survey and Planning

A. 1-b, 2-c, 3-d, 4-a
B. 1-c, 2-b, 3-a, 4-d
C. 1-d, 2-a, 3-c, 4-b
D. 1-a, 2-d, 3-b, 4-c

Answer: A

Explanation:

• Chopra → Drugs Enquiry

• Bhore → Health Survey and Development

• Mudaliar → Health Survey and Planning

• Hathi → Pharmaceutical Industry

19. Which combination is correctly matched?

A. R. N. Chopra: Drugs Enquiry Committee
B. Joseph Bhore: Hathi Committee
C. A. Lakshmanaswami Mudaliar: Drugs Enquiry Committee
D. Jaisukhlal Hathi: Health Survey and Development Committee

Answer: A

Explanation: Lt. Col. R. N. Chopra chaired the Drugs Enquiry Committee. Joseph Bhore chaired the Health Survey and Development Committee, Mudaliar chaired the Health Survey and Planning Committee, and Jaisukhlal Hathi chaired the committee on the drug and pharmaceutical industry.

G. Higher-Order Conceptual Questions

20. A student is asked to identify the committee that represents the earliest major systematic investigation into India's drug-related problems. Which should be selected?

A. Bhore Committee
B. Hathi Committee
C. Chopra Committee
D. Mudaliar Committee

Answer: C

Explanation: The Chopra Committee (1930–31) was the earliest among these committees to systematically investigate India's drug-related problems and helped establish the need for organized drug regulation.

21. Which statement best distinguishes the Bhore Committee from the Hathi Committee?

A. Bhore focused mainly on the pharmaceutical industry, whereas Hathi focused on health services.
B. Bhore focused on comprehensive health development, whereas Hathi focused on the drug and pharmaceutical industry.
C. Both committees dealt exclusively with pharmacy education.
D. Both committees were constituted before independence.

Answer: B

Explanation: This distinction is important: Bhore = health system development, whereas Hathi = drug and pharmaceutical industry.

22. A question asks: “Which committee should be recalled when the subject is strengthening India's health services rather than regulation of medicines?” The best answer is:

A. Hathi Committee
B. Chopra Committee
C. Mudaliar Committee
D. Drugs Enquiry Committee

Answer: C

Explanation: The Mudaliar Committee dealt with health services and health planning, whereas Chopra and Hathi were more directly related to drugs and pharmaceuticals.

23. If a question gives the clues “1974, pharmaceutical industry, drug availability, pricing and indigenous production,” which committee is being described?

A. Chopra Committee
B. Bhore Committee
C. Mudaliar Committee
D. Hathi Committee

Answer: D

Explanation: The combination of 1974 + pharmaceutical industry + drug availability/pricing strongly identifies the Hathi Committee.

24. Which of the following represents the BEST conceptual relationship among the four committees?

A. All four committees dealt primarily with pharmacy education.
B. Chopra initiated systematic examination of drug problems, Bhore addressed comprehensive health development, Mudaliar reviewed health services, and Hathi examined the pharmaceutical industry.
C. Bhore and Mudaliar dealt exclusively with drug pricing, while Chopra and Hathi dealt with hospitals.
D. All four committees were established after independence.

Answer: B

Explanation: This option correctly captures the distinct historical roles of the four committees and is more useful for understanding than simply memorizing years.

25. An examination question asks which committee would be most relevant to understanding the historical transition from identifying deficiencies in India's drug supply and regulation to examining the structure and performance of the pharmaceutical industry. Which pair is most appropriate?

A. Bhore and Mudaliar
B. Chopra and Hathi
C. Mudaliar and Bhore
D. Bhore and Hathi

Answer: B

Explanation: Chopra represents the early systematic investigation of drug-related problems, while Hathi later examined the drug and pharmaceutical industry. Together they illustrate an important evolution in India's pharmaceutical policy.

High-Yield Revision Table

• Committee Year Chairman Core Area

• Drugs Enquiry Committee (Chopra) 1930–31 Lt. Col. R. N. Chopra Drugs, quality, import, manufacture and distribution

• Health Survey & Development Committee (Bhore) 1946 Sir Joseph Bhore Comprehensive health development; preventive + curative care

• Health Survey & Planning Committee (Mudaliar) 1962 Dr. A. Lakshmanaswami Mudaliar Review and strengthening of health services

• Hathi Committee 1974 Jaisukhlal Hathi Drug & pharmaceutical industry; availability, production and pricing

Easy Memory Chain

C → B → M → H

Chopra → Bhore → Mudaliar → Hathi

1930–31 → 1946 → 1962 → 1974

A useful conceptual sequence is:

Drugs → Health Development → Health Planning → Pharmaceutical Industry

Exam Tip: Questions are frequently constructed by mixing up chairman, year, committee name and subject area. For advanced preparation, memorize these four dimensions together rather than learning the committee names in isolation.

Dr. Alok Bains